This page shows the latest Non-muscle-invasive bladder cancer news and features for those working in and with pharma, biotech and healthcare.
Despite the withdrawal, AZ still has several phase 3 trials testing Imfinzi in various treatment combinations for early- and late-stage bladder cancer. ... This includes the phase 3 NILE trial in metastatic disease, the phase 3 NIAGARA trial in muscle
AZ’s head of oncology José Baselga said that Imfinzi is still in a “comprehensive” phase 3 programme in bladder cancer. ... pre-surgery) bladder cancer treatment, and the POTOMAC study, which include subjects with non-muscle invasive bladder
of brain cancer. ... and non-muscle invasive bladder cancer.
for non-muscle-invasive bladder cancer (NMIBC), extending its lead in the checkpoint inhibitor market. ... NMIBC is the most commonly encountered form of bladder cancer, accounting for around 75% of the 80, 000 new cases of bladder cancer seen every year
The Oncologic Drugs Advisory Committee (ODAC) voted nine to four that Keytruda (pembrolizumab) should be approved for the treatment of certain patients with high-risk, non-muscle-invasive bladder cancer (NMIBC), ... Merck estimates more than 80, 000 new
Merck &Co/MSD – already dominating non-small cell lung cancer with Keytruda (pembrolizumab) – will have overall survival data for its drug in first-line squamous head and neck cancer from the ... It will also have mid-stage data on the drug as a
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...